Developer docs
API playgroundTry for free, no card

Search company profiles

Rapport Therapeutics

Full company profile

uuid00002vi

Namestring
Rapport Therapeutics
Legal namestring
RAPPORT THERAPEUTICS, Inc.
Websiteurl
rapportrx.com
Company typeenum
Public
Founded yearint
2022
Descriptiontext

Rapport Therapeutics is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Boston, Massachusetts, with a research and discovery office in San Diego. The company develops precision small molecule medicines for central nervous system (CNS) disorders using its proprietary RAP (Receptor-Associated Protein) Technology Platform, which is grounded in foundational discoveries regarding neuronal receptor complexes — principal subunits and their associated regulatory proteins (RAPs) that govern receptor expression and function. By targeting specific receptor variants such as TARPγ8 (expressed selectively in the hippocampus, amygdala, and cortex), the company aims to deliver CNS-active medicines with neuroanatomical specificity and improved tolerability relative to broadly distributed receptor modulators.

The company's lead asset is RAP-219, a TARPγ8-selective AMPA receptor negative allosteric modulator in Phase 3 development for drug-resistant focal onset seizures, with expansion into bipolar mania, primary generalized tonic-clonic seizures, and diabetic peripheral neuropathic pain following FDA clearance and lifting of a prior clinical hold. Phase 2a data demonstrated 77.8-90% median seizure reduction and 24% seizure freedom over 8 weeks, supporting acceleration of pivotal Phase 3 trials (FOCUS 1 and FOCUS 2) into Q2 2026. Adjacent discovery programs target α6 nAChR for chronic pain and α9α10 nAChR for hearing disorders. Lead customers (in the absence of commercial products) are limited to clinical trial participants across global Phase 3 sites and a single licensing counterparty, Tenacia Biotechnology, for Greater China rights.

The business model is presently pre-revenue. Reported FY2025 revenue of approximately $20 million reflects a discrete partnership-related payment rather than recurring product sales. Revenue going forward is expected to derive from pharmaceutical product sales of approved assets (commercial build-out is not yet established), supplemented by licensing and milestone economics such as the Tenacia deal ($20M upfront, up to $308M in milestones, tiered royalties). Distribution of investigational drug currently occurs through clinical trial sites. The company is publicly traded on NASDAQ (RAPP) following a June 2024 IPO and a December 2025 public offering, with approximately $490.5M in cash providing runway into the second half of 2029.

Short descriptiontext

Rapport Therapeutics is a clinical-stage biopharmaceutical company developing precision small molecule medicines for central nervous system disorders. Its lead candidate, RAP-219, is a TARPγ8-selective AMPA receptor modulator in Phase 3 trials for drug-resistant focal onset seizures, with pipeline expansion into bipolar mania and neuropathic pain.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision neuroscience therapeutics, small molecule CNS drugs, neurology pipeline development, epilepsy clinical research, clinical-stage biopharmaceutical
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neurology Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue will be generated through sales of approved pharmaceutical products, primarily RAP-219 and other pipeline candidates, upon successful regulatory approval and commercialization.

finance.yahoo.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Partnership with Tenacia Biotechnology for Greater China development and commercialization of RAP-219 provides $20M upfront payment plus up to $308M in potential development and commercialization milestones, plus mid-single to mid-teens tiered royalties on net sales.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Rapport Therapeutics develops a portfolio of precision small molecule drug candidates for central nervous system (CNS) disorders, anchored by lead candidate RAP-219, a TARPγ8-selective AMPA receptor negative allosteric modulator in Phase 3 development for focal onset seizures and expanding into bipolar mania and diabetic peripheral neuropathic pain. The portfolio is generated through the company's proprietary RAP Technology Platform, which enables neuroanatomically specific targeting of receptor variants. Additional discovery programs address α6 nAChR (chronic pain) and α9α10 nAChR (hearing disorders).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 77.8% median reduction in seizure frequency (Phase 2a focal onset seizures)
+4 more records
Product overview1 text field

Rapport Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of precision small molecule medicines for central nervous system (CNS) disorders. The company's lead product is RAP-219, a TARPγ8-selective AMPA receptor negative allosteric modulator in Phase 3 development for focal onset seizures (with expansion into bipolar mania and diabetic peripheral neuropathic pain). This is supported by the RAP Technology Platform, which enables precision targeting of receptor-associated proteins for neuroanatomical specificity. Additional pipeline programs include TARPγ8 AMPAR programs for epilepsy and nAChR programs (α6 for chronic pain, α9α10 for hearing disorders).

Product and service1 record
1RAP-219
CategoryLead Drug Candidate
Description

Clinical-stage oral small molecule designed as a TARPγ8-selective AMPA receptor negative allosteric modulator for the treatment of focal onset seizures, with planned or expanded development into bipolar mania and diabetic peripheral neuropathic pain; demonstrated 77.8% median reduction in seizure frequency in Phase 2a trials with 24% seizure freedom over 8 weeks.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Tenacia Biotechnology
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-09
Description

Strategic collaboration granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China (mainland China, Hong Kong, Macau, and Taiwan) for neurological indications including focal onset seizures and bipolar mania. Rapport receives $20M upfront, up to $308M in potential milestones, and mid-single to mid-teens tiered royalties. Tenacia leads Phase 3 trial expansion in China while Rapport retains global rights elsewhere.

globenewswire.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Xenon is a clinical-stage neuroscience company developing XEN1101, a selective Kv7.2/7.3 potassium channel opener for focal onset seizures, with additional neurology pipeline assets. It is one of the closest direct competitors to RAP-219 in drug-resistant focal epilepsy with a similarly precision-oriented CNS strategy.

TypeDirect peer
Description

Praxis is a clinical-stage CNS company developing precision therapies for genetic epilepsies and other neurological disorders, including ulixertinib and other small molecule programs. It competes directly with Rapport in the precision epilepsy space targeting underserved seizure populations.

TypeDirect peer
Description

Marinus developed ganaxolone (ZTALMY), an FDA-approved neurosteroid for seizures associated with CDKL5 deficiency disorder, and continues CNS epilepsy development. It is a direct comparable as a small-cap clinical/commercial-stage neurology company focused on seizure disorders.

TypeDirect peer
Description

Longboard was a clinical-stage CNS company developing bexicaserin (LP352), a 5-HT2C superagonist for refractory epilepsies and other CNS indications, before being acquired by Lundbeck in 2024. It is a direct peer in clinical-stage precision epilepsy drug development.

TypeDirect peer
Description

Cerevel was a clinical-stage neuroscience company developing precision therapies for CNS disorders including schizophrenia, epilepsy, and Parkinson's, led by Rapport's current CEO Abe Ceesay as President, before being acquired by AbbVie in 2024. It is a near-direct peer in CNS precision medicine strategy and pipeline approach.

TypeDirect peer
Description

Karuna developed xanomeline-trospium (Cobenfy) for schizophrenia before being acquired by Bristol Myers Squibb in 2024. Its clinical-stage CNS focus, IPO trajectory, and CFO background (Rapport's CFO Troy Ignelzi led Karuna's financings) make it a closely comparable peer in CNS drug development and exit dynamics.

TypeDirect peer
Description

Sage developed zuranolone (ZURZUVAE) for postpartum depression and continues CNS pipeline work. It is a clinical-stage neuroscience peer with comparable patient population focus (CNS disorders), precision mechanism approach, and small-cap public biotech trajectory.

8SK Biopharmaceuticals
TypeDirect peer
Description

SK Biopharmaceuticals developed cenobamate (XCOPRI), approved for focal onset seizures, and is a direct competitor in the drug-resistant focal epilepsy market that RAP-219 is targeting. Comparable in therapeutic focus and indication alignment.

TypeBroad incumbent
Description

UCB is a global biopharmaceutical company with a substantial neurology franchise including brivaracetam (Briviact) and other anti-epileptic drugs. It is a broad incumbent competitor in the focal epilepsy space and a likely benchmark for commercial execution in the indication.

TypeDirect peer
Description

Biohaven developed CGRP inhibitors for migraine (Nurtec ODT) and pursued neuroscience pipeline expansion before parts were acquired by Pfizer. It is a peer in clinical-stage CNS/neurology drug development with comparable public-biotech commercialization trajectory.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rapport Therapeutics

Neurology Pharmaceuticalsrapportrx.com

Rapport Therapeutics is a clinical-stage biopharmaceutical company developing precision small molecule medicines for central nervous system disorders. Its lead candidate, RAP-219, is a TARPγ8-selective AMPA receptor modulator in Phase 3 trials for drug-resistant focal onset seizures, with pipeline expansion into bipolar mania and neuropathic pain.

What Rapport Therapeutics does

Rapport Therapeutics is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Boston, Massachusetts, with a research and discovery office in San Diego. The company develops precision small molecule medicines for central nervous system (CNS) disorders using its proprietary RAP (Receptor-Associated Protein) Technology Platform, which is grounded in foundational discoveries regarding neuronal receptor complexes — principal subunits and their associated regulatory proteins (RAPs) that govern receptor expression and function. By targeting specific receptor variants such as TARPγ8 (expressed selectively in the hippocampus, amygdala, and cortex), the company aims to deliver CNS-active medicines with neuroanatomical specificity and improved tolerability relative to broadly distributed receptor modulators.

The company's lead asset is RAP-219, a TARPγ8-selective AMPA receptor negative allosteric modulator in Phase 3 development for drug-resistant focal onset seizures, with expansion into bipolar mania, primary generalized tonic-clonic seizures, and diabetic peripheral neuropathic pain following FDA clearance and lifting of a prior clinical hold. Phase 2a data demonstrated 77.8-90% median seizure reduction and 24% seizure freedom over 8 weeks, supporting acceleration of pivotal Phase 3 trials (FOCUS 1 and FOCUS 2) into Q2 2026. Adjacent discovery programs target α6 nAChR for chronic pain and α9α10 nAChR for hearing disorders. Lead customers (in the absence of commercial products) are limited to clinical trial participants across global Phase 3 sites and a single licensing counterparty, Tenacia Biotechnology, for Greater China rights.

The business model is presently pre-revenue. Reported FY2025 revenue of approximately $20 million reflects a discrete partnership-related payment rather than recurring product sales. Revenue going forward is expected to derive from pharmaceutical product sales of approved assets (commercial build-out is not yet established), supplemented by licensing and milestone economics such as the Tenacia deal ($20M upfront, up to $308M in milestones, tiered royalties). Distribution of investigational drug currently occurs through clinical trial sites. The company is publicly traded on NASDAQ (RAPP) following a June 2024 IPO and a December 2025 public offering, with approximately $490.5M in cash providing runway into the second half of 2029.

Rapport Therapeutics firmographics

Firmographics
Name
Rapport Therapeutics
Legal name
RAPPORT THERAPEUTICS, Inc.
Website
https://rapportrx.com
Company type
Public
Founded year
2022
Operating status
Operating
Headcount range
101–250 employees
Short description
Rapport Therapeutics is a clinical-stage biopharmaceutical company developing precision small molecule medicines for central nervous system disorders. Its lead candidate, RAP-219, is a TARPγ8-selective AMPA receptor modulator in Phase 3 trials for drug-resistant focal onset seizures, with pipeline expansion into bipolar mania and neuropathic pain.
Ownership category
akta.pro rank

Rapport Therapeutics industry classification

Industry
Product category
Neurology Pharmaceuticals
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Precision neuroscience therapeutics
  • Small molecule CNS drugs
  • Neurology pipeline development
  • Epilepsy clinical research
  • Clinical-stage biopharmaceutical

Where Rapport Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Rapport Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Revenue will be generated through sales of approved pharmaceutical products, primarily RAP-219 and other pipeline candidates, upon successful regulatory approval and commercialization.
  2. Licensing and Milestone Payments: Partnership with Tenacia Biotechnology for Greater China development and commercialization of RAP-219 provides $20M upfront payment plus up to $308M in potential development and commercialization milestones, plus mid-single to mid-teens tiered royalties on net sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Rapport Therapeutics product offering

Product offering

Core offering

Rapport Therapeutics develops a portfolio of precision small molecule drug candidates for central nervous system (CNS) disorders, anchored by lead candidate RAP-219, a TARPγ8-selective AMPA receptor negative allosteric modulator in Phase 3 development for focal onset seizures and expanding into bipolar mania and diabetic peripheral neuropathic pain. The portfolio is generated through the company's proprietary RAP Technology Platform, which enables neuroanatomically specific targeting of receptor variants. Additional discovery programs address α6 nAChR (chronic pain) and α9α10 nAChR (hearing disorders).

Product overview

Rapport Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of precision small molecule medicines for central nervous system (CNS) disorders. The company's lead product is RAP-219, a TARPγ8-selective AMPA receptor negative allosteric modulator in Phase 3 development for focal onset seizures (with expansion into bipolar mania and diabetic peripheral neuropathic pain). This is supported by the RAP Technology Platform, which enables precision targeting of receptor-associated proteins for neuroanatomical specificity. Additional pipeline programs include TARPγ8 AMPAR programs for epilepsy and nAChR programs (α6 for chronic pain, α9α10 for hearing disorders).

Differentiator

Problem solved

Functional benefit

Products and services

  • RAP-219 Clinical-stage oral small molecule designed as a TARPγ8-selective AMPA receptor negative allosteric modulator for the treatment of focal onset seizures, with planned or expanded development into bipolar mania and diabetic peripheral neuropathic pain; demonstrated 77.8% median reduction in seizure frequency in Phase 2a trials with 24% seizure freedom over 8 weeks.

Quantifiable outcome

  • 77.8% median reduction in seizure frequency (Phase 2a focal onset seizures)
  • +4 more outcomes

Companies that use Rapport Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Rapport Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Rapport Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Tenacia BiotechnologycoreOEM/ Whitelabel/ Licensing Partner · 9 March 2026Strategic collaboration granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China (mainland China, Hong Kong, Macau, and Taiwan) for neurological indications including focal onset seizures and bipolar mania. Rapport receives $20M upfront, up to $308M in potential milestones, and mid-single to mid-teens tiered royalties. Tenacia leads Phase 3 trial expansion in China while Rapport retains global rights elsewhere.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Rapport Therapeutics competitors and assessment

Company assessment

Direct peers

  • Xenon Pharmaceuticals: Xenon is a clinical-stage neuroscience company developing XEN1101, a selective Kv7.2/7.3 potassium channel opener for focal onset seizures, with additional neurology pipeline assets. It is one of the closest direct competitors to RAP-219 in drug-resistant focal epilepsy with a similarly precision-oriented CNS strategy.
  • Praxis Precision Medicines: Praxis is a clinical-stage CNS company developing precision therapies for genetic epilepsies and other neurological disorders, including ulixertinib and other small molecule programs. It competes directly with Rapport in the precision epilepsy space targeting underserved seizure populations.
  • Marinus Pharmaceuticals: Marinus developed ganaxolone (ZTALMY), an FDA-approved neurosteroid for seizures associated with CDKL5 deficiency disorder, and continues CNS epilepsy development. It is a direct comparable as a small-cap clinical/commercial-stage neurology company focused on seizure disorders.
  • Longboard Pharmaceuticals: Longboard was a clinical-stage CNS company developing bexicaserin (LP352), a 5-HT2C superagonist for refractory epilepsies and other CNS indications, before being acquired by Lundbeck in 2024. It is a direct peer in clinical-stage precision epilepsy drug development.
  • Cerevel Therapeutics: Cerevel was a clinical-stage neuroscience company developing precision therapies for CNS disorders including schizophrenia, epilepsy, and Parkinson's, led by Rapport's current CEO Abe Ceesay as President, before being acquired by AbbVie in 2024. It is a near-direct peer in CNS precision medicine strategy and pipeline approach.
  • Karuna Therapeutics: Karuna developed xanomeline-trospium (Cobenfy) for schizophrenia before being acquired by Bristol Myers Squibb in 2024. Its clinical-stage CNS focus, IPO trajectory, and CFO background (Rapport's CFO Troy Ignelzi led Karuna's financings) make it a closely comparable peer in CNS drug development and exit dynamics.
  • Sage Therapeutics: Sage developed zuranolone (ZURZUVAE) for postpartum depression and continues CNS pipeline work. It is a clinical-stage neuroscience peer with comparable patient population focus (CNS disorders), precision mechanism approach, and small-cap public biotech trajectory.
  • SK Biopharmaceuticals: SK Biopharmaceuticals developed cenobamate (XCOPRI), approved for focal onset seizures, and is a direct competitor in the drug-resistant focal epilepsy market that RAP-219 is targeting. Comparable in therapeutic focus and indication alignment.
  • Biohaven Pharmaceuticals: Biohaven developed CGRP inhibitors for migraine (Nurtec ODT) and pursued neuroscience pipeline expansion before parts were acquired by Pfizer. It is a peer in clinical-stage CNS/neurology drug development with comparable public-biotech commercialization trajectory.

Broad incumbents

  • UCB: UCB is a global biopharmaceutical company with a substantial neurology franchise including brivaracetam (Briviact) and other anti-epileptic drugs. It is a broad incumbent competitor in the focal epilepsy space and a likely benchmark for commercial execution in the indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Rapport Therapeutics social profiles

Digital presence

Rapport Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rapport Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Rapport Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rapport Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rapport Therapeutics

What does Rapport Therapeutics do?

Rapport Therapeutics develops a portfolio of precision small molecule drug candidates for central nervous system (CNS) disorders, anchored by lead candidate RAP-219, a TARPγ8-selective AMPA receptor negative allosteric modulator in Phase 3 development for focal onset seizures and expanding into bipolar mania and diabetic peripheral neuropathic pain. The portfolio is generated through the company's proprietary RAP Technology Platform, which enables neuroanatomically specific targeting of receptor variants. Additional discovery programs address α6 nAChR (chronic pain) and α9α10 nAChR (hearing disorders).

Is Rapport Therapeutics a public or private company?

Rapport Therapeutics is a public company. It is classified as public and is currently operating.

When was Rapport Therapeutics founded?

Rapport Therapeutics was founded in 2022. It employs 101 to 250 people.

Where is Rapport Therapeutics based?

Rapport Therapeutics is headquartered in Boston, United States, in the North America region.

How does Rapport Therapeutics make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Milestone Payments.

Who are Rapport Therapeutics's main competitors?

Direct peers on record are Xenon Pharmaceuticals, Praxis Precision Medicines, Marinus Pharmaceuticals, Longboard Pharmaceuticals, Cerevel Therapeutics, Karuna Therapeutics, Sage Therapeutics, SK Biopharmaceuticals and Biohaven Pharmaceuticals. UCB is listed as a broad incumbent.

Does Rapport Therapeutics have an API?

No public API is recorded for Rapport Therapeutics.

What industry is Rapport Therapeutics in?

Rapport Therapeutics's product category is Neurology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comRapport Therapeutics at jefferies global healthcare conference: pipeline gainsRapport Therapeutics presented phase II proof-of-concept data for RAP-219 in epilepsy and bipolar mania at the Jefferies Global Healthcare Conference. The drug showed a 71% reduction in electrographic seizures and a 3.1 placebo-adjusted YMRS difference in bipolar mania. The company has $814 million in cash, funding operations through 2029, with phase III studies planned.Investing.comRapport Therapeutics at stifel 2026 healthcare conference: cash-rich pushRapport Therapeutics presented proof-of-concept for RAP-219 in epilepsy and bipolar mania at the Stifel 2026 Healthcare Conference. The company has about $815 million in cash, funding work through 2029, and plans Phase III trials with an FDA meeting in early 2025.TradingViewInsider Buying Signals: 3 Healthcare Stocks to WatchJonathan Rose identifies Prothena, Rapport Therapeutics, and Azenta as healthcare stocks to watch based on insider buying and buybacks. Prothena's major shareholder bought 27,000 shares, Rapport's directors bought $1.66 million, and Azenta repurchased 4.4 million shares. He cites upcoming clinical data and fiscal 2027 growth outlook as catalysts.TradingViewUBS maintains Rapport Therapeutics at Buy, lowers price target to $64 from $71UBS maintained Rapport Therapeutics at Buy and lowered its price target to $64 from $71, a 9.9% decrease. The target implies an upside of 169.8% from the Nov 5 close of $23.72. Recent analyst price targets range from $47 to $89.Investing.comStifel reiterates Rapport Therapeutics stock rating on epilepsy focusStifel reiterated a Buy rating and $56 price target on Rapport Therapeutics after its Q3 2026 earnings, with the stock trading at $25.83. The firm cited positive phase 2 data in bipolar mania, where RAP-219 showed a 3-point effect size on YMRS, and noted the company is running two phase 3 studies. Rapport is on track to share longer-term safety data in Q4 2026.Business & FinancialRapport Therapeutics To Participate In Upcoming Investor ConferencesRapport Therapeutics will present at Stifel's 2026 Healthcare Conference in New York and Jefferies' Global Healthcare Conference in London. The company's lead investigational drug RAP-219 targets epilepsy and bipolar mania, with additional programs in chronic pain, migraine, and hearing disorders.Stock TitanRapport Therapeutics to join two investor conferencesRapport Therapeutics announced management will participate in two investor conferences: Stifel's in New York on November 11 and Jefferies' in London on November 16. The company will present its lead drug RAP-219 for epilepsy and bipolar mania, with webcasts available on its website.Investing.comTop insider buys and sells disclosed FridayInsider trading activity on October 28-30, 2026, included buys by directors of Rapport Therapeutics, Corebridge Financial, and Pinnacle Financial Partners, and sells by executives of Datadog, Dutch Bros, FedEx, and Cheesecake Factory. The transactions totaled over $100 million, with some purchases signaling confidence and others reflecting portfolio adjustments.Business & FinancialRapport Announces Closing Of Public Offerings Of Common Stock And Pre-Funded Warrants And Convertible Notes, Including Full Exercise Of Underwriters' Options To Purchase Additional Shares And Notes, As Well As Concurrent Private PlacementRapport Therapeutics closed its public offerings of common stock, pre-funded warrants, and convertible notes, including full exercise of underwriters' options, generating approximately $410.7 million in net proceeds. The company will use the funds primarily for clinical trials of RAP-219, R&D, and working capital, with no commitments to in-license or acquire businesses.YahooRapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private PlacementRapport Therapeutics closed its public offerings of common stock, pre-funded warrants, and convertible notes, including full exercise of underwriters' options, and a concurrent private placement. The offerings raised approximately $410.7 million in net proceeds, which the company will use primarily for clinical trials of RAP-219, R&D, and working capital.